Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 46 Lung Neoplasms 26 Carcinoma, Hepatocellular 22 Small Cell Lung Carcinoma 17 Urinary Bladder Neoplasms 11 Cholangiocarcinoma 10 Breast Neoplasms 10 Biliary Tract Neoplasms 10 Liver Neoplasms 9 Neoplasms 8 Neoplasm Metastasis 8 Pancreatic Neoplasms 5 Triple Negative Breast Neoplasms 4 Non-Muscle Invasive Bladder Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Transitional Cell 4 Carcinoma 4 Stomach Neoplasms 3 Respiratory Tract Neoplasms 3 Ovarian Neoplasms 3 Neoplasms by Site 3 Gallbladder Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Renal Cell 3 Bile Duct Neoplasms 3 Adenocarcinoma 3 Thyroid Neoplasms 2 Thoracic Neoplasms 2 Sarcoma 2 Respiratory Tract Diseases 2

Interventions

Cisplatin 21 Magnetic Resonance Spectroscopy 16 Specimen Handling 14 Platinum 12 1,2-diaminocyclohexaneplatinum II citrate 11 Radiotherapy, Intensity-Modulated 10 Radiation 10 Radiotherapy 9 Carboplatin 9 pembrolizumab 5 Surveys and Questionnaires 5 Biopsy 5 Taxes 4 Paclitaxel 4 Nivolumab 4 Docetaxel 4 Chemoradiotherapy 4 Observation 3 Fluorodeoxyglucose F18 3 Cetuximab 3 X-Rays 2 Watchful Waiting 2 Surgical Procedures, Operative 2 Standard of Care 2 Radiotherapy, Image-Guided 2 Interviews as Topic 2 Fluorouracil 2 (225)Ac-DOTA-c(RGDyK) 2 toripalimab 1 peposertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Oropharyngeal Neoplasms × durvalumab × 90 days × Clear all

NCT04116047 2026-05-07

CompARE

University of Birmingham

Phase 3 Active not recruiting

Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡